Assessee's Long Term Capital Gains appeal dismissed for tax evasion scheme; AO's findings upheld.

The Tribunal dismissed the appeal of the assessee concerning the legitimacy of Long Term Capital Gains claimed, determining the share transactions were part of a tax evasion scheme. The AO's findings were upheld, as the assessee failed to prove the transactions' genuineness, leading to the addition of unexplained cash credit. The Tribunal found no reason to interfere with the lower authorities' conclusions, upholding the dismissal of the assessee's appeal on 26th November 2019.

---

---

Issues Involved:
1. Legitimacy of Long Term Capital Gains (LTCG) claimed by the assessee.
2. Assessment of whether the share transactions were genuine or part of a tax evasion scheme.
3. Evaluation of the evidence and the burden of proof.
4. Procedural fairness regarding the opportunity for cross-examination.

Detailed Analysis:

1. Legitimacy of Long Term Capital Gains (LTCG) Claimed by the Assessee:
The primary issue revolves around the legitimacy of the LTCG claimed by the assessee, who declared an income of Rs. 3,26,210 for the Assessment Year 2014-15 and claimed an LTCG exemption under section 10(38) of the Income Tax Act, 1961, on the sale of shares of M/s Kappac Pharma Ltd. The Assessing Officer (AO) observed an astronomical return of approximately 6300% over a short period, prompting a deeper investigation into the price movements and share market behavior of the entities involved.

2. Assessment of Whether the Share Transactions Were Genuine or Part of a Tax Evasion Scheme:
The AO concluded that the share transactions were not genuine, based on a detailed examination of the trading history, financials of M/s Kappac Pharma Ltd, and reports from the investigation wing, Kolkata, and SEBI. The AO determined that the transactions were part of a meticulously planned circular trading scheme designed to convert unaccounted money into tax-exempt income. The AO's findings were corroborated by confessions from brokers, operators, and exit providers, leading to the addition of Rs. 84,38,907 as unexplained cash credit under section 68 of the Act.

3. Evaluation of the Evidence and the Burden of Proof:
The assessee contended that the transactions were genuine, supported by valid documentation, and that the statements from the investigation wing were admitted without an opportunity for cross-examination. The CIT(A) upheld the AO's findings, concluding that the assessee failed to discharge the burden of proving the genuineness of the transactions. The CIT(A) referred to established case law, including CIT vs. Durga Prasad More and Sumati Dayal vs. CIT, to support the conclusion that the transactions were sham and aimed at tax evasion.

4. Procedural Fairness Regarding the Opportunity for Cross-Examination:
The assessee argued that the assessment proceedings were vitiated due to the lack of an opportunity to cross-examine the individuals whose statements were recorded by the investigation wing. However, the Tribunal found that the AO's conclusions were based on independent investigations and not solely on the statements from the investigation wing, thus no prejudice was caused to the assessee.

Conclusion:
The Tribunal, after reviewing the record and submissions, concluded that the share transactions were surrounded by suspicion and the assessee failed to dispel this suspicion. The AO's findings were based on a thorough analysis of the financials of M/s Kappac Pharma Ltd and other relevant circumstances. The Tribunal upheld the orders of the authorities below, finding no reason to interfere with their conclusions. Consequently, the appeal of the assessee was dismissed.

Order Pronounced:
The appeal of the assessee was dismissed, and the order was pronounced in the Open Court on 26th November 2019.

---